Clinical observation of HAG regimen in remission inductive treatment for elderly patients with acute myeloid leukemia and myelodysplastic syndrome
10.3760/cma.j.issn.1009-9921.2011.03.007
- VernacularTitle:HAG预激化疗作为诱导缓解方案治疗老年人急性髓系白血病和骨髓增生异常综合征的临床观察
- Author:
Jianli WANG
;
Aili HE
;
Wanggang ZHANG
;
Yun YANG
;
Liufang GU
;
Ying KONG
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Myelodysplastic syndrome;
Aged;
Drug therapy,combination
- From:
Journal of Leukemia & Lymphoma
2011;20(3):151-153
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of HAG regimen in remission inductive treatment for elderly patients with acute myeloid leukemia (AML) and myelodysplastic syndrome-refractory anemia with excess blasts (MDS-RAEB). Methods The clinical features of 21 cases with AML and 9 cases with MDSRAEB (≥60 year old) treated with HA-G regimen in remission induction were retrospectively analyzed,including the complete remission (CR) rate, efficiency rate as well as their toxicities. Results In 21 elderly patients with AML treated with HAG regimen, the efficiency rate was 66.7 % (14/21), CR rate 47.6 % (10/21).In 9 elderly patients with MDS-RAEB, the CR rate was 55.6 % (5/9). The main toxicity of HA-G regimen was infections secondary to hematopoiesis suppression after chemotherapy. All patients were well tolerated to adjusted regimen. Conclusion The HA-G regimen is much effective in remission induction for elderly patients with AML and MDS-RAEB.